Brugada Syndrome (BrS) presents a particularly challenging clinical field for cardiologists due to its associated potentially lethal and often unpredictable arrhythmic risk [1]. While secondary prevention in patients with documented ventricular arrhythmias is relatively straightforward, leading to the inevitable implantation of an implantable cardioverter-defibrillator (ICD), primary prevention is more debated. The challenge lies in effectively protecting the patient from sudden cardiac death (SCD) while avoiding overtreatment and potential complications from defibrillator implantation [2].
